The poster will discuss the Phase 2 trial of ozuriftamab vedotin, a ROR2-targeted antibody-drug conjugate, for patients with heavily pretreated squamous cell carcinoma of the head and neck.

The cancer cells (magenta) lack the noncanonical Wnt receptor, Ror2. The protein fibronectin (orange) is up-regulated and assembled by Ror2-deficient tumor cells, triggering the invasion, ...

One of these is ozuriftamab vedotin, a CAB-ROR2 ADC in a phase 2 trial for HPV-positive squamous cell carcinoma of the head and neck. This population is “poorly served” by EGFR inhibitors ...

a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic ...

a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic ...

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...